GRI Bio Inc. (GRI)

GRI Bio Inc. (GRI) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4.2M; returns 1 day +2.1%, 1 week +5.1%, 1 year -97.4%.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases. Their lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells, being developed for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF).

Groups GRI belongs to

• Biotechnology
• Recent Reverse Splits
• Clinical Stage Biopharma
• Autoimmune Diseases
• Fibrosis
• Healthcare
• Biopharmaceutical
• Life Sciences
• Chronic Inflammatory Diseases
• Clinical Stage

GRI financial model: income statement, cash flow and balance sheet